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Abstract
Background Anticoagulant therapy is associated with a high risk of complications. Adherence to anticoagulant therapy pro-
tocols may lower this risk but adherence is often suboptimal. The introduction of a multidisciplinary antithrombotic team 
may improve adherence to anticoagulant guidelines among physicians. Objective To determine the effect of hospital-based 
multidisciplinary antithrombotic stewardship on adherence to anticoagulant guidelines among prescribing physicians. Set-
ting This prospective non-randomised before-and-after study was conducted in patients hospitalized between October 2015 
and December 2017 and treated with anticoagulant therapy. Method A multidisciplinary antithrombotic team focusing on 
education, medication reviews, drafting of local anticoagulant therapy protocols, patient counseling and medication rec-
onciliation at admission and discharge was implemented in two Dutch hospitals. Main outcome measure Primary outcome 
was the proportion of the admitted patients in which the prescribing physician did adhere to the anticoagulant guidelines. 
Results The study comprised 1886 patients, of which 941 patients were included in the usual care period and 945 patients 
in the intervention period. Multivariable logistic regression analysis indicated that adherence was observed significantly 
more often during the intervention period (adjusted odds ratio [ORadj] 1.58, 95% confidence interval [95% CI] 1.21–2.05). 
Detailed analysis identified that the significantly higher overall adherence in the intervention period was attributed to dosing 
of LMWHs (odds ratio [OR] 1.58, 95% CI 1.16–2.14). Conclusion This study shows that introduction of a multidisciplinary 
antithrombotic stewardship leads to a significantly higher overall adherence to anticoagulant guidelines among prescribing 
physicians, mainly based on the improvement of dosing of low-molecular-weight-heparins.
Keywords Adherence · Anticoagulant therapy · Antithrombotic stewardship · Complex intervention · The Netherlands
Impacts on Practice
• Multidisciplinary antithrombotic stewardship can play 
an important role in the improvement of adherence to 
anticoagulant guidelines among prescribing physicians.
• Education, medication reviews, drafting of local anti-
coagulant therapy protocols, patient counseling and 
medication reconciliation at admission and discharge are 
effective interventions to improve guideline adherence.
Introduction
Anticoagulant therapy is associated with a high risk of 
complications [1–3]. Medication errors with anticoagulants 
are among the most common causes leading to harm [4, 5]. 
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Guidelines and protocols are developed to improve prescrib-
ing quality and thus patient outcomes, and to reduce varia-
tion in clinical practice [6]. However, a discrepancy exists 
between recommended care and daily clinical practice [7]. 
In earlier studies of non-adherence to guidelines concerning 
proton pump inhibitor prescription in hospitalized patients 
who are prescribed NSAIDs, diabetes medication and dosing 
of medication in patients with impaired renal function, non-
adherence by physicians varied between 33 and 70% [8–10].
Studies evaluating partial and/or complete compliance 
with the American College of Chest Physicians (ACCP) 
venous thromboembolism (VTE) prevention guidelines, 
published between 2005 and 2008, showed that compliance 
rates ranged from 2.8 to 84% [11]. Proietti and colleagues 
assessed adherence in a cohort of atrial fibrillation (AF) 
acutely admitted patients. They concluded that only 40.9% 
of the patients were treated according to the European Soci-
ety of Cardiology (ESC) guideline and guideline-adherent 
treatment was independently associated with a significantly 
lower risk of all-cause and cardiovascular (CV) death [12].
Several strategies to improve guideline adherence have 
been described. Education programs together with com-
puter-based clinical decision support systems showed sig-
nificant improvements in adherence to guidelines for venous 
thromboembolism in hospitals [13]. Bos et al. [14] showed 
that education of hospital prescribers combined with audit 
and feedback by hospital pharmacists reduced physician 
non-adherence to guidelines covering pain management, 
antithrombotics, fluid and electrolyte management, appli-
cation of radiographic contrast agents and surgical antibiotic 
prophylaxis. Furthermore, Maynard and colleagues evalu-
ated the impact of the implementation of a multidiscipli-
nary team on inpatient anticoagulation and management of 
venous thromboembolism in 189 patients with 211 identified 
VTE events [15]. Interventions consisted of education, com-
puter prescriber-order-entry system (CPOE) upgrades, clini-
cal decision support, triggered consultation, and checklists. 
Warfarin adjustment by protocol improved from 70 to 96% 
and warfarin-heparin overlap improved from 26 to 74% after 
the implementation of the multidisciplinary team. However, 
compliance to low-molecular-weight heparins (LMWHs) 
showed no increase and mortality and readmission rates did 
not change significantly. The results from previous studies 
showed that compliance with guidelines of different drugs 
varied widely and that compliance depends not only on 
type of drug but also on the clinical situation in which the 
drug is prescribed (e.g. acute care versus ambulatory care) 
[8–10]. Of course, depending on the situation other factors 
such as patient preferences may be more important than 
strict adherence to the guideline. Nevertheless, literature 
clearly shows there is room for improvement. Despite the 
fact that the same compliance with the prescribing guide-
lines for all drugs cannot be expected, there is still room for 
improvement. Moreover, existing anticoagulant intervention 
studies focused on patients treated with warfarin or low-
molecular-weight-heparins (LMWHs) and do not concern 
patients using other vitamin K antagonists (VKAs) or direct 
oral anticoagulants (DOACs).
Aim of the study
The aim of our study was to determine the effect of hos-
pital-based multidisciplinary antithrombotic stewardship 
on adherence to anticoagulant guidelines by prescribing 
physicians.
Ethics approval
Approval was obtained from the Medical Ethics Committee 
of the Erasmus University Medical Center (MEC-2015-386).
Methods
Study design
This study was designed as a prospective non-randomised 
before-and-after study, with the intervention being the 
implementation of a multidisciplinary antithrombotic team. 
Therefore a 9-month period of usual care and a 9-month 
intervention period were compared.
This study was a sub-study of a larger antithrombotic 
stewardship study (S-team study), in which the effect of a 
multidisciplinary antithrombotic team was evaluated on the 
safety and efficacy of antithrombotic therapy during hospi-
talization [16].
Study setting
The study was conducted in the Erasmus University Medical 
Center (EMC) and the Reinier de Graaf Hospital (RdGG). 
The EMC is a 1320-bed University Medical Center based in 
Rotterdam, the Netherlands. The RdGG is a general teaching 
hospital located in Delft, the Netherlands, with 590 beds.
Study population
Patients admitted to the EMC or RdGG between October 
2015 and December 2017 and treated with anticoagulant 
therapy were eligible for inclusion. The study population 
consisted of patients who started on anticoagulant therapy 
in the hospital, patients who were already treated with anti-
coagulant therapy before hospitalization and patients who 
restarted anticoagulant therapy after a surgical or non-sur-
gical intervention. Only the patient’s first hospital admission 
was included. All participants provided informed consent 
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during hospitalization. Exclusion criteria were the follow-
ing: (1) no informed consent from the patient (or the par-
ents/guardian of the patient), (2) hospitalization for less than 
24 h, (3) admission to the intensive care unit (ICU) without 
previous admission to a general care ward, (4) patients who 
received only LMWHs as thrombosis prophylaxis.
Data collection
Data were collected from electronic patient records in the 
hospital information systems (HiX; Chipsoft, Amsterdam, 
the Netherlands and Elpado; homegrown system Erasmus 
University Medical Center, Rotterdam, the Netherlands) 
(Table S1). The bleeding risk of the surgical procedure 
(high, low, and clinically non-relevant bleeding risk) was 
defined according to the ‘Richtlijn Antithrombotisch Beleid’ 
(Dutch guideline on antithrombotic policy) [17]. Patient data 
were coded according to Dutch privacy guidelines. Data 
were collected during hospital stay from the day of hospi-
talization or from the day of discharge from the ICU to a 
general care ward until discharge from hospital or patient 
death. In patients who were initially admitted to a general 
care ward and subsequently transferred to the ICU, data were 
collected from the day of hospitalization until admission to 
the ICU. All data were processed with Open Clinica (Open 
Clinica LLC, Waltham, USA).
Usual care
During the usual care period the normal procedures of medi-
cation surveillance by hospital pharmacists and physicians 
were maintained. The pharmacy software automatically 
checks the prescribed medication in relation to the medica-
tion record that is available within the pharmacy system and 
automatically generates medication surveillance alerts with a 
pop-up in case of drug–drug interactions, over- or underdose 
(dose ranges dependent on age, bodyweight and gender), 
duplications and contraindications. These medication sur-
veillance alerts were easily dismissible by physicians. Fur-
thermore, clinical rules were used in patients using DOACs 
or LMWHs. Clinical rules combine the renal function of 
the patient with the prescribed drug to assess whether dose 
adjustments should be made based on the renal function. A 
detailed description of the procedures during the usual care 
period can be found in the study protocol [16].
Intervention
The previously published study protocol provides a detailed 
description of the antithrombotic team [16]. The interven-
tion consisted of the implementation of a multidisciplinary 
antithrombotic team. The team in the University Medical 
Center consisted of a specialized thrombosis nurse as case 
manager, a hematologist, a pediatric hematologist, a hema-
tologist (head) of the regional thrombosis service, a hos-
pital pharmacist/clinical pharmacologist, a cardiologist, an 
anesthesiologist, a pulmonologist, a neurologist, a (vascular)
surgeon and a quality officer. In the general hospital, the 
team consisted of a specialized thrombosis nurse as case 
manager, a hematologist, a hospital pharmacist, a cardiolo-
gist, an anesthesiologist and a clinical chemist. A neurolo-
gist, pulmonologist, pediatrician, emergency physician and 
(orthopedic) surgeon were added to the team when neces-
sary. The teams focused on the following interventions:
Education
To increase the knowledge of antithrombotic therapy among 
physicians, nurses and hospital pharmacists, hospital-wide 
education was given.
Medication reviews by (hospital) pharmacists
Daily structured medication reviews were performed by the 
(hospital) pharmacist focused on optimizing treatment with 
anticoagulants. The pharmacotherapy review focused on 
dosing (i.e., in relation to decreased renal function, body 
weight and age), duplicate medication, drug–drug inter-
actions, contraindications and perioperative bridging of 
anticoagulants.
Antithrombotic therapy guidelines
Local guidelines were drafted based on recent national 
guidelines and updated to ensure there was a uniform policy 
on antithrombotic therapy.
Patient counseling
The purpose of patient counseling was to provide informa-
tion and education to patients with the aim of giving the 
patient more control and responsibility over their own health 
and healthcare. Such patient empowerment was performed 
on daily basis for each included patient.
Medication reconciliation
At admission, data from the patients thrombosis service 
regarding dosing scheme, indication for anticoagulation, 
type of VKA, INR measurements and the INR target range 
were handed over to the responsible physician. At discharge, 
pharmacotherapy advice from the medication review were 
handed over to either the thrombosis service or the general 
practitioner, and to the community pharmacist.
694 International Journal of Clinical Pharmacy (2019) 41:691–699
1 3
Guidelines
Adherence to anticoagulant guidelines was assessed by 
using prevailing anticoagulant therapy guidelines which 
are implemented in the local hospital protocols. Seven 
guidelines were selected at which the adherence was easy 
to score. The guidelines focused on drug–drug interactions 
in patients using VKAs, dosing of LMWHs in relation to 
renal function and bodyweight and perioperative bridging of 
anticoagulants. The four separate guidelines regarding direct 
oral anticoagulants (drug–drug interactions in patients using 
DOACs, dosing of rivaroxaban versus renal function, dos-
ing of dabigatran versus renal function and age, and dosing 
of apixaban versus serum creatinine, body weight and age) 
were clustered for the analysis into one pharmacotherapeutic 
DOAC measure because of the low number of DOAC users, 
resulting in a total of four guidelines. Table 1 shows the 
prevailing anticoagulant guidelines.
Outcome measures
Primary outcome was the proportion of the admitted patients 
in which the prescribing physician adhered to one or more of 
the anticoagulant guidelines (the total number of admitted 
patients was included as denominator). Secondary outcome 
was the proportion of the prescriptions in which the pre-
scribing physician adhered to each of the four anticoagulant 
guidelines (for the prescribed anticoagulant(s) each patient 
was on, the total number of applicable guidelines and oppor-
tunities for adherence was calculated and included in the 
denominator).
Sample size
This study has been powered on the outcome measure of 
the S-team study, in which the effect of a multidisciplinary 
antithrombotic team on the safety and efficacy regarding 
antithrombotic therapy during hospitalization is studied [16]. 
With a type 1 error of 0.05, power of 80%, the required sam-
ple size was 917 patients in the usual care period and 917 
patients in the intervention period. In order to account for 
drop-outs, 1900 patients were included.
Data analysis
All data were analyzed with IBM SPSS version 21.0 (IBM 
Software, New York, USA). All continuous variables were 
tested for normality with the Shapiro–Wilk test. Non-nor-
mal variables were expressed as medians and interquartile 
ranges (IQR) and differences between groups tested with the 
Mann–Whitney U test. Categorical variables were presented 
as percentages and tested for statistical significance between 
groups using the Chi square test. P < 0.05 was considered to 
be statistically significant. Odds ratios (OR) and 95% confi-
dence intervals (95% CI) for each of the four anticoagulant 
guidelines were obtained by logistic regression analysis, 
with the time period (intervention period versus usual care 
period) as primary variable. In order to adjust for possible 
predictors, multivariable logistic regression analysis was 
performed. The following possible predictors were initially 
entered into the model: age, length of hospitalization, hos-
pital type, surgery and treatment with VKAs, DOACs or 
LMWHs. Variables that changed the beta-coefficient with 
more than 10% were retained in the model. Adjusted odds 
ratios (ORadj) and 95% confidence intervals (95% CI) were 
reported.
Results
Study population
During the study period 2577 patients were eligible for inclu-
sion. In 677 patients, at least one reason for exclusion was 
present. Fourteen patients withdrew their consent after signing 
the informed consent due to medical reasons. Thus, in total 
1886 patients were included in our analysis, which included 
941 patients in the usual care period and 945 patients in the 
intervention period (Fig. 1). Characteristics of the included 
patients are presented in Table 2. Of these, the majority in 
both groups were male and the median age was 69 years. 
There were no differences between the two groups in gender, 
age, prior thrombotic event, hospital type, weight, renal func-
tion and high and low bleeding risk of the surgical procedure 
(in cases where the patients had to undergo surgery).
Patients included in the intervention period had a shorter 
hospital stay (p < 0.001), had more prior bleeding events 
(p < 0.001) and a larger number of patients had a surgi-
cal procedure with a clinically non-relevant bleeding risk 
(p = 0.032). The use of VKAs (p < 0.001) and LMWHs 
(p = 0.002) was less in patients in the intervention group 
but the use of DOACs was higher (p < 0.001).
Adherence to anticoagulant guidelines
Table 3 shows the proportions of the admitted patients in 
which the prescribing physician adhered to one or more of 
the anticoagulant guidelines. Logistic regression analysis 
revealed that the overall adherence was significantly higher 
in the intervention period [75.3% (497/660)] compared to 
the usual care period [63.4% (395/623)] (odds ratio [OR] 
1.76, 95% confidence interval [95% CI] 1.38–2.24). After 
adjustment for the possible predictors (i.e. age, length of 
hospitalization, hospital type, surgery and treatment with 
VKAs, DOACs or LMWHs), the adjusted OR was 1.58 (95% 
CI 1.21–2.05). As shown in Table 3, the significantly higher 
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overall adherence in the intervention period was attributed 
to dosing of LMWHs in relation to renal function and body-
weight. The odds ratio was 1.58 (95% CI 1.16–2.14). The 
other guidelines (drug–drug interactions in patients using 
VKAs, perioperative bridging of anticoagulants and dosing 
of DOACs) showed no significant differences between the 
usual care period and intervention period.
The proportions of the prescriptions in which the pre-
scribing physician adhered to each of four anticoagulant 
guidelines occurred in 569 out of 811 (70.2%) prescrip-
tions in the usual care period and in 657 out of 834 
(78.8%) prescriptions in the intervention period. After 
adjustment for the same possible predictors, the adjusted 
odds ratio was 1.42 (95% CI 1.12–1.80).
Table 1  Guidelines based on prevailing anticoagulant therapy guidelines
VKA Vitamin K antagonist, DOAC Direct Oral Anticoagulant, LMWH Low Molecular Weight Heparin, SmPC Summary of Product Characteris-
tics, EMC Erasmus University Medical Center, RdGG Reinier de Graaf Hospital, INR International Normalized Ratio, ACCP American College 
of Chest Physicians
Pharmacotherapeutic measure Effectuation measurement of protocol adher-
ence
Reference
1. VKA and interacting drugs cotrimoxazole, 
miconazole, fluconazole, voriconazole, ami-
odarone, rifampicin, rifabutin and rifaximin
All patients with an active prescription of 
interacting drugs at the same time the VKA 
was prescribed, were checked whether the 
VKA or the interacting drug was discon-
tinued and replaced by an alternative drug 
24 h after the start of the combination OR 
whether the INR was monitored after starting 
the combination of the interacting drug and 
the VKA (within 36 h after the start of the 
combination with cotrimoxazole, micona-
zole, fluconazole, voriconazole and amiodar-
one AND within 5 days after the start of the 
combination with rifampicin, rifabutin and 
rifaximin)
Dutch national G-standard [18]
SmPC VKA [19]
2a. DOAC and interacting drugs ketoconazole, 
itraconazole, voriconazole, cyclosporin, 
tacrolimus, rifampicin, phenobarbital, phe-
nytoin, carbamazepine and verapamil
All patients with an active prescription of 
interacting drugs at the same time the DOAC 
was prescribed, were checked whether the 
DOAC or the interacting drug was discontin-
ued and replaced by an alternative drug 24 h 
after the start of the combination. Patients 
treated with verapamil and dabigatran at the 
same time, were checked whether the dose of 
dabigatran was adjusted
Dutch national G-standard [18]
SmPC DOAC [20]
2b. Rivaroxaban versus renal function All patients treated with rivaroxaban, were 
checked whether the dose of rivaroxaban was 
adjusted based on the renal function
Dutch national G-standard [18]
SmPC Rivaroxaban [21]
2c. Dabigatran versus renal function and age All patients treated with dabigatran were 
checked whether the dose of dabigatran was 
adjusted based on the renal function and 
patient age
Dutch national G-standard [18]
SmPC Dabigatran [22]
2d. Apixaban versus serum creatinine, body 
weight and age
All patients treated with apixaban were 
checked whether the dose of apixaban was 
adjusted based on the serum creatinine, body 
weight and patient age
Dutch national G-standard [18]
SmPC Apixaban [23]
3. LMWH versus renal function and body-
weight
All patients treated with therapeutic doses 
of tinzaparin or nadroparin were checked 
whether the doses of the LMWHs were 
adjusted based on the renal function and 
patient body weight
EMC: Vademecum hematology [24] & Dutch 
national G-standard [18]
RdGG: SmPC tinzaparine [25] & Dutch 
national G-standard [18]
4. Pre-operative INR value All patients undergoing surgery using VKAs, 
were checked whether the pre-operative INR 
value 24 h before surgery was adequate. The 
cut-off pre-operative INR value was based on 
the bleeding risk of the surgical procedure: 
high (INR ≤ 1.5), low (INR ≤ 2.0), and clini-
cally non-relevant bleeding risk (INR ≤ 3.0)
Pre-operative cut-off INR values (ACCP 
guideline) [26]
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Discussion
The overall adherence to anticoagulant guidelines was 
significantly higher after the implementation of a multi-
disciplinary antithrombotic team focusing on education, 
medication reviews, drafting of local anticoagulant therapy 
protocols, patient counseling and medication reconciliation. 
The significantly higher overall adherence in the interven-
tion period can be attributed to the improvement of dosing 
of LMWHs in relation to renal function and bodyweight.
Earlier multifaceted intervention studies also showed 
a positive impact on guideline and protocol adherence. 
Maynard et al. [15] revealed that implementation of a mul-
tidisciplinary team, focusing on patients with identified 
Fig. 1  Study flow
Patients eligible for inclusion
(n=2,577)
Patients with informed consent
(n=1,900)
Inclusion
(n=1,886)
Patients excluded (677):
Not adequate (n=361)
No informed consent (n=174)
Other reason (n=142)
Withdrawn consent (n=14)
Table 2  Baseline characteristics 
of the patients
Figures in bold are statistically significant
Results are presented as median [interquartile range] or as number of patients (%) for non-continues data. 
N, number of patients at risk; e-GFR estimated glomerular filtration rate
*Patients can use multiple anticoagulants during hospitalization
Characteristic Usual care period 
(n = 941)
Intervention period 
(n = 945)
p value
Male gender 562 (59.7) 578 (61.2) 0.522
Age, years 69 [59–77] 69 [59–77] 0.665
Length of hospitalization, days 8 [5–14] 7 [3–13] < 0.001
Prior bleeding 198 (21.0) 269 (28.5) < 0.001
Prior thrombotic event 448 (47.6) 461 (48.8) 0.610
Hospital type, University Medical Center 472 (50.2) 472 (49.4) 0.927
Weight 80 [70–91] 80 [70–93] 0.177
e-GFR, ≤ 50 ml/min/1.73 m2 301 (33.0) 266 (30.1) 0.189
Surgery 340 (36.1) 330 (34.9) 0.583
Bleeding risk surgical procedure
High bleeding risk 243 (25.8) 212 (22.4) 0.085
Low bleeding risk 57 (6.1) 62 (6.6) 0.653
Clinically non-relevant bleeding risk 40 (4.3) 60 (6.3) 0.032
Type of anticoagulant therapy*
Vitamin K antagonist 646 (68.7) 553 (58.5) < 0.001
Direct oral anticoagulant 80 (8.5) 263 (27.8) < 0.001
Low-molecular-weight-heparin 488 (51.9) 423 (44.8) 0.002
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VTE events and treated with warfarin or LMWHs led to 
improved inpatient anticoagulation and management of 
venous thromboembolism. Bos et al. introduced an educa-
tional program for prescribers in the hospital combined with 
audit and feedback by the hospital pharmacist. This led to 
a significant decrease in non-adherence from 30.5 to 21.8% 
of prescribing physicians to key pharmacotherapeutic guide-
lines, such as gastric protection in case of use of NSAID in 
hospitalized surgical patients and perioperative bridging of 
antithrombotics [14]. Other multifaceted intervention stud-
ies focusing on antibiotics found an increase in the rate of 
guideline adherence of antibiotic prescription [27, 28]. The 
hypothesis that a multifaceted approach is the most effec-
tive method to improve protocol adherence is supported by 
a previous study of Worel et al. [11] who described that 
lack of audit tools and feedback systems and the presence 
of an abundance of guidelines with conflicting recommen-
dations result in lack of guideline adherence. Furthermore, 
passive dissemination of guidelines alone is often insuffi-
cient to have a positive impact on guideline adherence [13]. 
This study shows that the implementation of a multidisci-
plinary antithrombotic team leads to a significant increase 
in adherence to anticoagulant guidelines, specifically dosing 
of LMWHs. The improvement was obtained on top of other 
measures as medication surveillance by hospital pharmacists 
and clinical rules, which were part of usual care. Further-
more, active strategies such as education and medication 
reviews are needed to increase the knowledge and skills of 
prescribing physicians and thereby improve the adherence of 
guidelines. Comparing the different intervention studies on 
protocol adherence with each other is difficult given that the 
interventions in the various studies differ from each other. 
Moreover, this study focused on anticoagulant guidelines 
including patients treated with VKAs and DOACs while 
other studies focused mainly on patients treated with war-
farin or LMWHs for specific indications, such as VTE. The 
significant increase in the number of DOAC users during the 
intervention period compared to the usual care period may 
be explained with as in 2016 (at the time of the intervention 
period) DOACs have been recommended as the first choice 
treatment of VTE [29].
The majority of overall adherence to anticoagulant guide-
lines was mainly caused by the improvement of dosing of 
LMWHs (OR 1.58 [95% CI 1.16–2.14]). Slikkerveer et al. 
[30] found that most prescribing errors with LMWH treat-
ment included overdosages and underdosages that were not 
correctly adjusted to body weight or renal function. The 
significantly higher adherence to dosing of LMWH therapy 
in the intervention period may be explained by the fact that 
during the intervention period medication reviews were 
performed by hospital pharmacists with attention paid to 
both bodyweight and renal function in relation to the dose 
of LMWHs. This differs from the usual care period where 
attention was only paid to the renal function in relation to 
dosing of LMWHs. Focusing on both body weight and 
renal function may have led to the improvement of dosing 
of LMWHs among prescribing physicians. LMWHs are one 
of the most frequently therapeutically prescribed anticoagu-
lants in hospitalized patients. Besides, as dosing is based 
on both bodyweight and renal function, prescribing errors 
occur frequently. This may have contributed to the fact that 
the greatest effect of the hospital-based multidisciplinary 
antithrombotic stewardship was seen on dosing of LMWHs. 
Guidelines concerning drug–drug interactions in patients 
using VKAs and DOACs, perioperative bridging of antico-
agulants and dosing of DOACs in relation to renal function, 
age and bodyweight showed no significant association in 
adherence of prescribing physicians after the implementa-
tion of a multidisciplinary antithrombotic team. A possible 
explanation is that during the usual care period the phar-
macy software automatically checked the prescribed medica-
tion in relation to the medication record that was available 
within the pharmacy system and automatically generated 
medication surveillance and signals in case of interactions, 
Table 3  Adherence of prescribing physicians to guidelines based on prevailing anticoagulant therapy protocols
Figures in bold are statistically significant
OR odds ratio, 95% CI 95% confidence interval, VKA Vitamin K antagonist, DOAC Direct Oral Anticoagulant, LMWH Low Molecular Weight 
Heparin, INR International Normalized Ratio
a OR, adjusted for predictors (age, length of hospitalization, hospital type, surgery and treatment with VKAs, DOACs or LMWHs)
Usual care period (n = 941) Intervention period (n = 945) OR [95% CI]
Adherence Adherence
1. VKA and interacting drugs 103/111 (92.8%) 74/81 (91.4%) 0.82 [0.29–2.36]
2. DOAC and interacting drugs, renal function, age 
and body weight
69/80 (86.3%) 228/263 (86.7%) 1.04 [0.50–2.15]
3. LMWH versus renal function and bodyweight 217/393 (55.2%) 204/309 (66.0%) 1.58 [1.16–2.14]
4. Pre-operative INR value 180/227 (79.3%) 151/181 (83.4%) 1.31 [0.80–2.18]
Overall adherence 395/623 (63.4%) 497/660 (75.3%) 1.76 [1.38–2.24]
1.58a [1.21–2.05]
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overdose, duplications and contraindications. In addition, the 
pre-operative INR value before surgery was already closely 
monitored by the physician during the usual care period. 
Despite the significant increase in adherence to anticoagu-
lant guidelines in this study, 24.7% of the prescribing phy-
sicians were non-adherent to the anticoagulant guidelines 
after implementation of the multidisciplinary antithrombotic 
team. Although this study showed that the implementation 
of a multidisciplinary antithrombotic team leaded to a sig-
nificant increase in adherence to anticoagulant guidelines, 
there still may be room for improvement.
Strengths and limitations
To our knowledge, this is the first study describing the effect 
of hospital-based multidisciplinary antithrombotic steward-
ship on the adherence to anticoagulant guidelines among pre-
scribing physicians. Furthermore, the study was performed in 
two different types of hospitals, a University Medical Center 
and a general teaching hospital, which increases the gener-
alizability of our findings. Another strength of this study is 
the multifaceted approach which combines different interven-
tions to improve the adherence to anticoagulant guidelines.
This study has several limitations. First, seven guidelines 
derived from several anticoagulant therapy protocols were 
selected. This is a limited set of anticoagulant guidelines 
and may not be generalizable to all anticoagulant protocols. 
A second limitation is that the cost-effectiveness of the 
intervention has not been analyzed. Additional costs were 
incurred by performing medication reviews, which were 
conducted by the hospital pharmacist. Furthermore, draft-
ing of local protocols and education to physicians and nurses 
were performed by healthcare providers, such as a special-
ized thrombosis nurse, a hematologist, a hospital pharmacist, 
and a cardiologist. Third, logistic regression analysis doesn’t 
take into consideration any clustering within prescriber (e.g. 
surgical versus medical). Fourth, this study is a prospective 
non-randomised before-and-after study, without a retrospec-
tive control group. Improvements may already have been 
implemented during the usual care period. Finally, the inter-
vention is multifaceted making it difficult to say which spe-
cific intervention (e.g. medication reviews) has been of the 
greatest influence on improvement of anticoagulant therapy 
protocol adherence among prescribing physicians.
Conclusion
This study showed that introduction of hospital-based mul-
tidisciplinary antithrombotic stewardship resulted in a sig-
nificantly higher overall adherence to anticoagulant guide-
lines among prescribing physicians, mainly based on the 
improvement of correct dosing of low-molecular-weight-
heparins. Future studies should focus whether higher adher-
ence to anticoagulant guidelines contributes to improvement 
in clinical outcomes.
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